However, our results showed that the BTK inhibitor ibrutinib affects neither NGAL-mediated CLL cell survival nor the NGAL-R expression level (Figure S3)—indicating that BTK is not involved in NGAL signaling. Here, SLC22A17 is linked to B-cell chronic lymphocytic leukemia.